Literature DB >> 21212411

VEGFR-1 expressed by malignant melanoma-initiating cells is required for tumor growth.

Natasha Y Frank1, Tobias Schatton, Soo Kim, Qian Zhan, Brian J Wilson, Jie Ma, Karim R Saab, Veronika Osherov, Hans R Widlund, Martin Gasser, Ana-Maria Waaga-Gasser, Thomas S Kupper, George F Murphy, Markus H Frank.   

Abstract

Melanoma growth is driven by malignant melanoma-initiating cells (MMIC) identified by expression of the ATP-binding cassette (ABC) member ABCB5. ABCB5(+) melanoma subpopulations have been shown to overexpress the vasculogenic differentiation markers CD144 (VE-cadherin) and TIE1 and are associated with CD31(-) vasculogenic mimicry (VM), an established biomarker associated with increased patient mortality. Here we identify a critical role for VEGFR-1 signaling in ABCB5(+) MMIC-dependent VM and tumor growth. Global gene expression analyses, validated by mRNA and protein determinations, revealed preferential expression of VEGFR-1 on ABCB5(+) tumor cells purified from clinical melanomas and established melanoma lines. In vitro, VEGF induced the expression of CD144 in ABCB5(+) subpopulations that constitutively expressed VEGFR-1 but not in ABCB5(-) bulk populations that were predominantly VEGFR-1(-). In vivo, melanoma-specific shRNA-mediated knockdown of VEGFR-1 blocked the development of ABCB5(+) VM morphology and inhibited ABCB5(+) VM-associated production of the secreted melanoma mitogen laminin. Moreover, melanoma-specific VEGFR-1 knockdown markedly inhibited tumor growth (by > 90%). Our results show that VEGFR-1 function in MMIC regulates VM and associated laminin production and show that this function represents one mechanism through which MMICs promote tumor growth. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21212411      PMCID: PMC3083845          DOI: 10.1158/0008-5472.CAN-10-1660

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  46 in total

1.  Protein kinase A-regulated nucleocytoplasmic shuttling of Id1 during angiogenesis.

Authors:  Koichi Nishiyama; Kentaro Takaji; Yasunobu Uchijima; Yukiko Kurihara; Tomoichiro Asano; Michihiro Yoshimura; Hisao Ogawa; Hiroki Kurihara
Journal:  J Biol Chem       Date:  2007-04-05       Impact factor: 5.157

2.  Targeting cancer stem cells through L1CAM suppresses glioma growth.

Authors:  Shideng Bao; Qiulian Wu; Zhizhong Li; Sith Sathornsumetee; Hui Wang; Roger E McLendon; Anita B Hjelmeland; Jeremy N Rich
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

3.  Stemming the flood.

Authors:  Keith S Hoek; Ossia M Eichhoff; Daniel Widmer; Reinhard Dummer
Journal:  Pigment Cell Melanoma Res       Date:  2008-12-23       Impact factor: 4.693

Review 4.  Cancer stem cells: mirage or reality?

Authors:  Piyush B Gupta; Christine L Chaffer; Robert A Weinberg
Journal:  Nat Med       Date:  2009-09-04       Impact factor: 53.440

5.  Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential.

Authors:  Elena Monzani; Floriana Facchetti; Enrico Galmozzi; Elena Corsini; Anna Benetti; Chiara Cavazzin; Angela Gritti; Andrea Piccinini; Danilo Porro; Mario Santinami; Gloria Invernici; Eugenio Parati; Giulio Alessandri; Caterina A M La Porta
Journal:  Eur J Cancer       Date:  2007-02-22       Impact factor: 9.162

Review 6.  Cancer stem cells and human malignant melanoma.

Authors:  Tobias Schatton; Markus H Frank
Journal:  Pigment Cell Melanoma Res       Date:  2008-02       Impact factor: 4.693

7.  MDR1 expression identifies human melanoma stem cells.

Authors:  Gilmor I Keshet; Itamar Goldstein; Orit Itzhaki; Karen Cesarkas; Liraz Shenhav; Arkadi Yakirevitch; Avraham J Treves; Jacob Schachter; Ninette Amariglio; Gideon Rechavi
Journal:  Biochem Biophys Res Commun       Date:  2008-02-13       Impact factor: 3.575

8.  In vivo switching of human melanoma cells between proliferative and invasive states.

Authors:  Keith S Hoek; Ossia M Eichhoff; Natalie C Schlegel; Udo Döbbeling; Nikita Kobert; Leo Schaerer; Silvio Hemmi; Reinhard Dummer
Journal:  Cancer Res       Date:  2008-02-01       Impact factor: 12.701

9.  Suppression subtractive hybridization profiles of radial growth phase and metastatic melanoma cell lines reveal novel potential targets.

Authors:  Josane F Sousa; Enilza M Espreafico
Journal:  BMC Cancer       Date:  2008-01-22       Impact factor: 4.430

10.  Efficient tumour formation by single human melanoma cells.

Authors:  Elsa Quintana; Mark Shackleton; Michael S Sabel; Douglas R Fullen; Timothy M Johnson; Sean J Morrison
Journal:  Nature       Date:  2008-12-04       Impact factor: 49.962

View more
  81 in total

1.  Host-derived pericytes and Sca-1+ cells predominate in the MART-1- stroma fraction of experimentally induced melanoma.

Authors:  J Humberto Treviño-Villarreal; Douglas A Cotanche; Rosalinda Sepúlveda; Magda E Bortoni; Otto Manneberg; Taturo Udagawa; Rick A Rogers
Journal:  J Histochem Cytochem       Date:  2011-12       Impact factor: 2.479

Review 2.  Altered gene products involved in the malignant reprogramming of cancer stem/progenitor cells and multitargeted therapies.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Mol Aspects Med       Date:  2013-08-29

Review 3.  Stem cells and targeted approaches to melanoma cure.

Authors:  George F Murphy; Brian J Wilson; Sasha D Girouard; Natasha Y Frank; Markus H Frank
Journal:  Mol Aspects Med       Date:  2013-10-19

4.  VEGFR-1 Pseudogene Expression and Regulatory Function in Human Colorectal Cancer Cells.

Authors:  Xiangcang Ye; Fan Fan; Rajat Bhattacharya; Seth Bellister; Delphine R Boulbes; Rui Wang; Ling Xia; Cristina Ivan; Xiaofeng Zheng; George A Calin; Jing Wang; Xiongbin Lu; Lee M Ellis
Journal:  Mol Cancer Res       Date:  2015-06-03       Impact factor: 5.852

Review 5.  Melanoma stem cells and metastasis: mimicking hematopoietic cell trafficking?

Authors:  Nayoung Lee; Steven R Barthel; Tobias Schatton
Journal:  Lab Invest       Date:  2013-10-14       Impact factor: 5.662

6.  Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy.

Authors:  Jenny Yao; Xiumin Wu; Guanglei Zhuang; Ian M Kasman; Tobias Vogt; Vernon Phan; Masabumi Shibuya; Napoleone Ferrara; Carlos Bais
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-27       Impact factor: 11.205

7.  ABCB5 identifies a therapy-refractory tumor cell population in colorectal cancer patients.

Authors:  Brian J Wilson; Tobias Schatton; Qian Zhan; Martin Gasser; Jie Ma; Karim R Saab; Robin Schanche; Ana-Maria Waaga-Gasser; Jason S Gold; Qin Huang; George F Murphy; Markus H Frank; Natasha Y Frank
Journal:  Cancer Res       Date:  2011-06-07       Impact factor: 12.701

Review 8.  Melanocytes, melanocyte stem cells, and melanoma stem cells.

Authors:  Deborah Lang; Joseph B Mascarenhas; Christopher R Shea
Journal:  Clin Dermatol       Date:  2013 Mar-Apr       Impact factor: 3.541

9.  Induction of Vasculogenic Mimicry Overrides VEGF-A Silencing and Enriches Stem-like Cancer Cells in Melanoma.

Authors:  Caroline I Schnegg; Moon Hee Yang; Subrata K Ghosh; Mei-Yu Hsu
Journal:  Cancer Res       Date:  2015-03-13       Impact factor: 12.701

10.  ABCB5 maintains melanoma-initiating cells through a proinflammatory cytokine signaling circuit.

Authors:  Brian J Wilson; Karim R Saab; Jie Ma; Tobias Schatton; Pablo Pütz; Qian Zhan; George F Murphy; Martin Gasser; Ana Maria Waaga-Gasser; Natasha Y Frank; Markus H Frank
Journal:  Cancer Res       Date:  2014-06-16       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.